Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;47(13):3176-3185.
doi: 10.1007/s00259-020-04880-1. Epub 2020 Jun 13.

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Affiliations

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Mark E Schmidt et al. Eur J Nucl Med Mol Imaging. 2020 Dec.

Abstract

Purpose: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer's disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [18F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer's disease to age-matched healthy controls.

Methods: [18F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [18F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [18F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [18F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5 h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region.

Results: One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [18F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120 min. Temporal and frontal cortical SUVr/DVR values in visually positive AD subjects ranged from 1.21 to 3.09/1.2 to 2.18 and from 0.92 to 1.28/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257 mSv/MBq for females and 0.0254 mSv/MBq for males.

Conclusions: [18F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates.

Keywords: Alzheimer’s disease; Isoquinoline; PET; Tau aggregates.

PubMed Disclaimer

Conflict of interest statement

Mark E. Schmidt, Luc Janssens, Diederik Moechars, Frederik J.R. Rombouts, Maarten Timmers, and Hartmuth Kolb are all full time employees of Janssen Research & Development, which provided funding and oversight of these studies and supported the discovery and preclinical characterization of JNJ-6436067. Olivier Barret, Cristian C. Constantinescu, Jennifer Madonia, David S. Russell, and Christine M. Sandiego are or were (OB, JM) full time employees of Invicro, a Konica Minolta company, New Haven, CT, USA, at the time of these studies.

Figures

Fig. 1
Fig. 1
Individual MRI (top), 60–90 min (middle), and 120–180 min (bottom). PET SUVr images from HV Subjects 13 (a), and 10 (b), and AD subjects 6 (c) and 11 (d). Signal in the occipital cortex in subject 10 underlie the location of pellets in the skull from a shotgun accident as a youth
Fig. 2
Fig. 2
a Representative [18F] JNJ-64326067 SUV time-activity curves HV and AD subjects. b [18F]JNJ-64326067 SUVr time-activity curves from the same HV and AD subjects. Abbreviations: medial frontal cortex (FL_Mid_L), inferior lateral temporal cortex (TL_InfLat_L), posterior cingulate (Cing_Post_L)
Fig. 3
Fig. 3
Regional SUVr values for all AD and HV subjects: cortical (a) and subcortical and mesial regions (b). FL frontal, OL occipital, TL temporal, Cing cingulate. Box represents the interquartile range (IQR); i.e., 25th–75th percentiles. Inside the box: median (horizontal line), mean (circle). Whiskers cover the data within 1.5 IQR. Circles outside the whiskers show the observations beyond the reach of the whiskers. Results for right and left were similar; left regions only are depicted for clarity
Fig. 4
Fig. 4
Regional DVR values for all AD and HV subjects: cortical (a) and subcortical and mesial regions (b). Abbreviations are the same as in Fig. 3. Results for right and left were similar; left regions only are depicted for clarity
Fig. 5
Fig. 5
Correlation of [18F] JNJ-64326067 DVR using 90 min of data, SUVr averaged between 30 and 60, 60–90, and 120–180 min with DVR using 180 min of data. DVR was estimated using LGA. The ventral cerebellum reference region was used for both SUVr and DVR. These regressions were done using regional values in AD subjects 06, 11, and 14
Fig. 6
Fig. 6
Bland–Altman plots of SUVr vs. DVR. Bland–Altman plots of SUVr vs. DVR for a 60–90 min and b 120–180 min for AD subjects 06, 11, and 14. Each point shows a pair of (SUVr, DVR) measures taken in the same subject × region. The x-coordinate is the average of (SUVr, DVR), and the y-coordinate is the difference (SUVr-DVR). The black horizontal line through y = 0: reference where SUVr = DVR. Above this line SUVr>DVR, and vice versa. The red horizontal line represents the trough of the mean of all difference observations. The red dotted lines indicate the 95% threshold for the differences (i.e., mean ± 2SD)

References

    1. Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981–988. - PMC - PubMed
    1. Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–547. - PMC - PubMed
    1. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457–468. - PubMed
    1. Ariza M, Kolb HC, Moechars D, Rombouts F, Andres JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58(11):4365–4382. - PubMed
    1. Baker SL, Harrison TM, Maass A, La Joie R, Jagust W. Effect of off-target binding on (18)F-Flortaucipir variability in healthy controls across the lifespan. J Nucl Med. 2019;60:1444–1451. 10.2967/jnumed.118.224113. - PMC - PubMed